financetom
Business
financetom
/
Business
/
Humana beats quarterly profit estimates on higher premiums, in-line medical costs
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Humana beats quarterly profit estimates on higher premiums, in-line medical costs
Nov 5, 2025 3:40 AM

(Reuters) -Humana reported third-quarter profit that beat Wall Street estimates on Wednesday, helped by higher premiums and medical costs which were in line with the health insurer's expectations.

The company is one of the largest providers of Medicare Advantage plans, under which the U.S. government pays private insurers a set rate to manage healthcare for people 65 and older, as well as those with disabilities.

The health insurance industry has been battling stubbornly high costs for the last two years due to the increased use of healthcare services across government-backed plans.

Humana has been making efforts to contain costs by repricing its plans and adjusting benefits to help boost profits.

It now expects a decline of about 425,000 members in its individual Medicare Advantage plans, an improvement from the loss of up to 500,000 members expected previously. This was driven by stronger member retention and better-than-expected sales.

"We view membership growth as positive supported by our 2026 MA pricing and the plan and benefit repositioning we drove in the prior two years," the company said in prepared remarks ahead of a call with analysts.

Humana expects most of its new members to be on higher-rated plans for 2026.

Its quarterly medical cost ratio - the percentage of premiums spent on medical care - came in at 91.1%. Humana said the medical cost ratio was in line with its expectations of "just above 91%". Analysts had expected a ratio of 90.90%, according to data compiled by LSEG.

It also reaffirmed its annual adjusted profit forecast of about $17 per share.

The company posted adjusted quarterly profit of $3.24 per share, surpassing estimates of $2.82 per share.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cruise operator Royal Caribbean beats Q3 adjusted EPS expectations, lifts FY forecast
Cruise operator Royal Caribbean beats Q3 adjusted EPS expectations, lifts FY forecast
Oct 28, 2025
Overview * Royal Caribbean Q3 adjusted EPS beats analyst expectations, driven by strong demand and lower costs * Company raises full-year 2025 adjusted EPS guidance to $15.58-$15.63, up 32% yr/yr Outlook * Royal Caribbean raises 2025 Adjusted EPS guidance to $15.58-$15.63 * Company says 2026 bookings have come in at rates well above the prior year * Company expects 2026...
Curbline Properties Q3 Operating FFO, Revenue Rise; Annual Operating FFO Guidance Upgraded
Curbline Properties Q3 Operating FFO, Revenue Rise; Annual Operating FFO Guidance Upgraded
Oct 28, 2025
06:44 AM EDT, 10/28/2025 (MT Newswires) -- Curbline Properties ( CURB ) reported Q3 operating funds from operations Tuesday of $0.28 per diluted share, up from $0.19 a year earlier. Four analysts polled by FactSet expected $0.27. Revenue for the quarter ended Sept. 30 was $48.6 million, up from $29.8 million a year earlier. Analysts surveyed by FactSet expected $42.9...
Regeneron Pharma's Q3 profit beats on Dupixent strength
Regeneron Pharma's Q3 profit beats on Dupixent strength
Oct 28, 2025
Overview * Regeneron Q3 2025 revenue grows 1% to $3.75 bln, beating analyst expectations * Adjusted EPS for Q3 2025 beats consensus, driven by strong product sales * Company reports strong sales growth for Dupixent and EYLEA HD Outlook * Regeneron updates 2025 R&D expense guidance to $5.68-$5.75 bln * Company revises 2025 SG&A expense guidance to $2.775-$2.845 bln *...
Zebra Technologies Q3 sales edge past estimates on lower-than-expected tariff impact
Zebra Technologies Q3 sales edge past estimates on lower-than-expected tariff impact
Oct 28, 2025
Overview * Zebra Q3 net sales rise 5.2% yr/yr, beating analyst expectations * Adjusted EPS for Q3 beats analyst expectations, reflecting strong operational performance * Company plans $500 mln share repurchase over next 12 months Outlook * Company expects Q4 sales growth between 8% and 11% * Adjusted EBITDA margin for Q4 expected to be around 22% * Non-GAAP EPS...
Copyright 2023-2026 - www.financetom.com All Rights Reserved